Prevention of exacerbations of chronic bacterial prostatitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

For the evaluation of the effectiveness of combined herbal drug ”prolit super septo” in the prevention of exacerbations of chronic bacterial prostatitis, an open prospective comparative ”case-control” study, which included 54 patients with a diagnosis of chronic bacterial prostatitis was performed. 27 patients received standard etiopathogenic therapy; other 27 patients in addition to standard therapy received prolit super septo 2 capsules twice a day for two months. 6 months after treatment, it was found that exacerbations occurred in 4 (14.8%) patients in the comparison group, and in 2 (7.4%) patients in the main group who received prolit super septo; in other patients sustained remission was achieved. In patients in the comparison group, the pain intensity of 3.2 points has persisted, and 2.8 points - in patients in the study group. A moderate increase of white blood count in the prostate secretion was more than 1.5 times often detected in the control group by than in the group of patients taking a prolit. Clinically significant bacterial growth was not observed in any patient. Quality of life of patients in the study group increased by 4.6 points, and in the comparison group - by 4.2 points

Full Text

Restricted Access

About the authors

E. V Kulchavenya

FSBI Novosibirsk SRI of Tuberculosis of RMPH; SBEI HPE Novosibirsk State Medical University of RMPH

Email: urotub@yandex.ru
MD, Prof., chief research scientist of the FSBI Novosibirsk SRI of Tuberculosis of RMPH, Prof. at the Department of Tuberculosis NSMU

A. A Breusov

Medical Center «BIOVER»

Novosibirsk

References

  1. Nickel J.C. Effective office management of chronic prostatitis. Urol Clin North Am. 1998; Nov; 25(4): 677-684.
  2. Nickel J.C., Downey J., Johnston B. et al. Canadian Prostatitis Research Group. Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial. J Urol. 2001; May; l65(5): 1539-1544.
  3. Wagenlehner F.M., Vahlensieck W., Bauer H.W. et al. Prevention of recurrent urinary tract infections. Minerva Urol Nefrol. 2013; Mar; 65(1): 9-20.
  4. Weidner W., Schiefer H.G., Krauss H. et al. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection. 1991; 19 Suppl 3: S119-125.
  5. Krieger J.N., Egan K.J., Ross S.O. et al. Chronic pelvic pains represent the most prominent urogenital symptoms of «chronic prostatitis». Urology. 1996; Nov; 48(5): 715-721.
  6. Krieger J.N., Jacobs R.R., Ross S.O. Does the chronic prostatitis/pelvic pain syndrome differ from nonbacterial prostatitis and prostatodynia? J Urol. 2000; Nov; 164(5): 1554-1558.
  7. Naber K.G., Weidner W. Prostatitits, epididymitis and orchitis. In: Armstrong D., Cohen J., eds. Infectious diseases. London: Mosby. 1999; Chapter 58.
  8. Naber K.G. Antimicrobial treatment of bacterial prostatitis. Eur Urol. 2003; 43(2): 23-26.
  9. Кульчавеня Е.В., Неймарк А.И. Инфекционно-воспалительные заболевания простаты: монография. Германия: Palmarium Academium Publishing. 2013. 169 с.
  10. Schaeffer A.J., Weidner W., Barbalias G.A. et al. Summary consensus statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2003; Aug; 43(2): 1-4.
  11. Alexander R.B., Propert K.J., Schaeffer A.J. et al; Chronic Prostatitis Collaborative Research Network. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med. 2004; Oct; 141(8): 581-589.
  12. Попков В.М., Блюмберг Б.И., Основин О.В. и др. «Пролит Cепто» в комплексном лечении больных острым пиелонефритом и нефролитиазом. Саратовский научно-медицинский журнал. 2011. Т. 7. № 2. С. 217.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies